TG Therapeutics

(NASDAQ) TGTX

Current Price$33.58

Market Cap$5.52B

Since IPO (2011)+2,943%

5 Year-20%

1 Year-18%

1 Month+9%

TG Therapeutics Financials at a Glance

Market Cap

$5.52B

Revenue (TTM)

$616.29M

Net Income (TTM)

$447.18M

EPS (TTM)

$2.78

P/E Ratio

12.45

Dividend

$0.00

Beta (Volatility)

1.83 (High)

Dividend

$0.00

Beta (Volatility)

1.83 (High)

Price

$33.58

Volume

1,829,155

Open

$34.02

Price

$33.58

Volume

1,829,155

Open

$34.02

Previous Close

$33.58

Daily Range

$33.28 - $34.19

52-Week Range

$25.28 - $46.48

Dividend

$0.00

Beta (Volatility)

1.83 (High)

Price

$33.58

Volume

1,829,155

Open

$34.02

Previous Close

$33.58

Daily Range

$33.28 - $34.19

52-Week Range

$25.28 - $46.48

TGTX News

A scientist looking through a microscope.

Best Biotech ETFs to Buy in 2026

Keith SpeightsApr 11, 2026

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop

Jonathan PoncianoMar 16, 2026

Page 1

TGTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TG Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

399

CEO

Michael Sean Weiss

Website

www.tgtherapeutics.com

Headquarters

Morrisville, NY 10014, US

TGTX Financials

Key Financial Metrics (TTM)

Gross Margin

84%

Operating Margin

20%

Net Income Margin

73%

Return on Equity

103%

Return on Capital

14%

Return on Assets

42%

Earnings Yield

8.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.52B

Shares Outstanding

159.69M

Volume

1.83M

Avg. Volume

1.89M

Financials (TTM)

Gross Profit

$515.33M

Operating Income

$123.32M

EBITDA

$134.36M

Operating Cash Flow

$24.77M

Capital Expenditure

$214.00K

Free Cash Flow

$24.99M

Cash & ST Invst.

$141.97M

Total Debt

$260.73M

TG Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$192.57M

+78.0%

Gross Profit

$154.37M

+66.4%

Gross Margin

80.16%

N/A

Market Cap

$5.52B

N/A

Market Cap/Employee

$15.69M

N/A

Employees

352

N/A

Net Income

$23.04M

-1.3%

EBITDA

$51.69M

+58.7%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$118.76M

-307.3%

Accounts Receivable

$305.63M

+136.6%

Inventory

$125.59M

+13.7%

Long Term Debt

$259.69M

+2.8%

Short Term Debt

$1.04M

-9.8%

Return on Assets

42.06%

N/A

Return on Invested Capital

13.56%

N/A

Free Cash Flow

$19.59M

+176.4%

Operating Cash Flow

$19.66M

+176.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IMVTImmunovant, Inc.

IMVTImmunovant, Inc.$26.95-0.15%

ALKSAlkermes plc

ALKSAlkermes plc$33.71-1.26%

PTCTPTC Therapeutics, Inc.

PTCTPTC Therapeutics, Inc.$64.55-8.13%

CRSPCRISPR Therapeutics AG

CRSPCRISPR Therapeutics AG$50.71-2.59%

PTGXProtagonist Therapeutics, Inc.

PTGXProtagonist Therapeutics, Inc.$98.52-2.66%

KYMRKymera Therapeutics, Inc.

KYMRKymera Therapeutics, Inc.$81.51-2.79%

ACLXArcellx, Inc.

ACLXArcellx, Inc.$115.07+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.14+0.04%

HOODRobinhood Markets

HOODRobinhood Markets$71.20-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.86+0.02%

KALVKalVista Pharmaceuticals

KALVKalVista Pharmaceuticals$26.67+0.39%

POETPoet Technologies

POETPoet Technologies$6.60-0.18%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.93-0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$53.08-0.02%

Questions About TGTX

What is the current price of TG Therapeutics?

TG Therapeutics is trading at $33.58 per share.

What is the 52-week range for TG Therapeutics?

Over the past 52 weeks, TG Therapeutics has traded between $25.28 and $46.48.

How much debt does TG Therapeutics have?

As of the most recent reporting period, TG Therapeutics reported total debt of $253.71M.

How much cash does TG Therapeutics have on hand?

TG Therapeutics reported $79.15M in cash and cash equivalents in its most recent financial results.

What is TG Therapeutics’s dividend yield?

TG Therapeutics does not currently have a dividend yield.

TG Therapeutics

TG Therapeutics Financials at a Glance

TGTX News

Best Biotech ETFs to Buy in 2026

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop

Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares

TG Therapeutics Q2 Revenue Up 91%

Why TG Therapeutics Stock Was Tumbling Today

Why TG Therapeutics Stock Was Soaring This Week

TG Therapeutics: Briumvi Revenue Soars

Why TG Therapeutics Stock Was Rocketing Higher This Week

TGTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About TG Therapeutics

TGTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

TG Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TGTX

What is the current price of TG Therapeutics?

What is the 52-week range for TG Therapeutics?

How much debt does TG Therapeutics have?

How much cash does TG Therapeutics have on hand?

What is TG Therapeutics’s dividend yield?

Premium Investing Services